We describe a time-resolved immunofluorometnc assay (TR-IFMA) for human 17-hydroxysteroid dehydrogenase (17HSD) in which antibody-coated microtiter strip wells and europium chelate-labeled polyclonal antibodies are used. In preparing the label, a polyclonal antibody is affinity-purified and denvatized with diethylenetnaminepentaacetic acid. With this derivative, five to eight europium ions can be combined with one antibody molecule without decreasing the antibody's immunoreactivity. The minimum detectable concentration of17HSD is 0.13 p.g/L; the intra-and interassay CVs are <8% and <15%, respectively, for concentrations between 0.3 and 100 pg/L There is no difference between the concentrations of 17HSD in plasma specimens taken during the proliferative and luteal phases of the menstrual cycle, the measured mean concentration being 0.22 g/L. We found no correlation between plasma 17HSD and progesterone concentrations. The plasma concentrations of 17HSD increase during pregnancy, the mean concentrations being 1.5, 4.4, and 12.5 g/L, during the first, second, and third trimesters of pregnancy, respectively. In the specimens from 18 men, the mean concentration was 0.18 g/L. In six plasma specimens from patients with endometrialadenocarcinoma, the mean concentrationwas 0.20 pg/L. Pre-analytical diol into the less potent estrogen, estrone (4). In the endometrium, the activity of this enzyme is regulated by progestins (1,2,5-7) .
diol into the less potent estrogen, estrone (4). In the endometrium, the activity of this enzyme is regulated by progestins (1, 2, (5) (6) (7) .
17HSD has been purified to homogeneity in this (8) and other laboratories (9,10) by using placental tissue as the starting material. Furthermore, we have raised polyclonal antibodies against the purified protein (8) and sequenced the cDNA of human placental 17HSD (11).
Circulating concentrations of 17HSD possibly reflect the functional status of steroid-forming or progesteroneregulated tissues. During pregnancy, blood concentrations of this enzyme might therefore reflect the state of the placenta, known to be a rich source of this enzyme (8-10). To this end, the enzymatic activity of 17HSD has been measured in the serum of pregnant women (12, 13) and in umbilical cord serum (13) . However, the lability of the enzyme activity has created problems in kinetic assays of the enzyme in serum (12 In this study, we used an inexpensive europium (Eu)-labeling method (17) to prepare a diethylenetriaminepentaacetic acid (DTPA) derivative of our polyclonal antibody (8) and developed a Th-IFMA for measuring circulating 17HSD.
MaterIals and Methods

Materials
Antigen.
We purified 17HSD to apparent homogeneity from human term placental tissue, as described previously (8). Antibody production and purification. By using the highly purified placental 17HSD as an immunogen, we raised polyclonal antibodies in rabbits. We used two of these antibodies to construct an immunometric assay. The equilibrium dissociation constants (Kd) of the antibodies were 3.7 x 10-" and 4.9 x 10" mol/L, as determined by Scatchard analysis (18). The antibodies were purified by affinity chromatography on a Sepharose-Protein A column (Pharmacia, Uppsala, Sweden). We used the antibody with greater affinity to prepare the labeled derivative; the other antibody was immobilized on solid phase.
Preparationof Eu-Labeled Antibody
Eu-labeling and purification of the labeled antibody were carried out as described previously (17) . We coijugated the affinity-purified antibody with the bicyclic anhydride of DTPA (cD'rPAA), using a cDTPAAIIgG molar ratio of 40/1 in the conjugation reaction. The plates were sealed in plastic bags and stored at 4#{176}C, where they were stable for at least six months.
17HSD TR-IFMA
The assay buffer we used was Tris HC1 (50 mmol/L, pH 7.5), containing, per liter, 9 g of NaCl, 5 g of bovine serum albumin, 0.5 g of bovine y-globulin, 0. We constructed the standard curve by using concentrations of 0, 0.3, 1, 3, 10, 30, and 100 ag/L of purified 17HSD in inactivated charcoal-treated human serum containing, per liter, 200 mL of glycerol. Duplicate 100-jL aliquots of each of the standard and plasma samples were pipetted into the coated wells. We then added 100 L of the assay buffer toeach well and incubated the contents for 4 h at room temperature on an automated shaker. We rinsed the wells six times with wash solution, using the Platewash device. 
ResuIts Antibodiesand Labeling
The antigen and the antibody with the Kd of 3.7 x 10_li mol/L have been described in detail already (8).
In the present study, we used an additional purified polyclonal antibody, raised against the purified 17HSD, as a capture antibody in an iminunometric assay.
The antibody with the Kd of 3.7 x 10_li mol/L was purified, derivatized with cDTPAA, and labeled with Eu. Five to eight Eu atoms could be combined with one IgG molecule.
Analytical Variables
A standard
curve for the Th-WMA of 17HSD is shown in Figure 1 .
Sensitivity. The lowest detectable concentration of 17HSD, defined as the concentration corresponding to the counts per second 3 SD above the mean of 18 replicate determinations of the zero ligand concentration, was calculated as 0.13 pg/L. Analytical recovery. We performed the recovery tests by adding known amounts of the purified analyte to blood plasma. We recovered 83-113% of 17HSD added in the concentration range of 3.1-33.4 pg/L. Linearity. We studied the effect of serialdilutions with three plasma samples, containing 17HSD at 8.7, 14.3,and 18.4 pg/L. The respective linear regression equations for the dilution curves werey = 0.99x + 0.05, y = 0.99x + 0.1,andy = 1.03x -0.9.
Precision.
We carried out the precision tests with plasma specimens from pregnant women. To determine within-mn variability (CV), we made six duplicate measurements of low (2.8 pg/L), medium (10.5pgfL), and high (25.2 pg/L) concentrations of 17HSD. The mean CVs for these measurements were 11.4%, 6.7%, and The known lability of the enzyme in kinetic assays was also evident in our immunometric assay. When stored at room temperature for only 24 h, -60% of the immunoreactivity was lost; this loss increased to -80% after 48 h. The corresponding losses were 35% and 62% when the specimens were stored at 4#{176}C. The stability of 17HSD in serum could be retained by adding glycerol, 200 mJJL final concentration, to the plasma and by freezing specimens within 2 h at -70 #{176}C. Under these conditions, the enzyme was stable for months.
Plasma Concentrationsof 17HSD
The mean plasma concentration of 17HSD in the apparently healthy men examined was 0.18 pg/L (range 0.0-0.48 .tg/L). There was no apparent association of the concentrations of 17HSD with age.
The concentrations of plasma 17HSD in the specimens from pre-menopausal, apparently healthy women taking no form of hormonal contraception are shown in Table 1 . There was no relation between the 17HSD concentrations and the phase of the menstrual cycle, nor with serum progesterone As expected, the method is characterized by high sensitivity, owing tothe high specific activity of the Eu-labeled polyclonal antibody tracer.
One problem encountered in evaluating the clinical importance of the measurements of circulating 17HSD concentrations is the lability of the enzyme. The use of different protease inhibitors did not prevent the loss of immunoreactivity. The only way we found to retain the antigemcity was to add glycerol to the samples without delay after the separation of the plasma. Perhaps this problem could be avoided by using monoclonal antibodies that interact with the more stable epitopes of the antigen.
The antigen was detectable in plasma from men, but in very low concentrations. At present, we have not ascertained the sources of this antigen. In men, 17f3-HSD activity has been detected in the steroid-forming tissues (2) and the prostate (19) (20) (21) .
The steroid-forming tissues could also be the source of the enzyme circulating in plasma from women. An additional source would be, at least theoretically, the endometriuxn.
However,
we found no increase in the concentrations of circulating 17HSD during the second half of the menstrual cycle. During this part of the cycle, 17HSD is present in increased concentrations in the endometrial epithelium (7, 8) because it is induced by the progesterone (5) secreted by the corpus luteum during the second half of the cycle. Our data show that these concentration changes of the enzyme in the endometrium are not reflected in its plasma concentrations and, therefore, the low amounts of circulating 17HSD may not be of endometrial origin.
The limited number of sertun specimens from patients with endometrial adenocarcinoma did not reveal any changes in the plasma concentrations of 17HSD. The increasing concentrations of 17HSD toward the end of pregnancy may reflect the increasing mass of the placental tissue and the associated increase in the turnover of placental cells. We do not know at present whether the concentrations of plasma 17HSD reflect disturbances in placental function.
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